QLS1403 / Qilu Pharma - LARVOL DELTA

QLS1403, a novel and potent PARG inhibitor with robust anti-tumor efficacy in homologous recombination deficient cancer models (AACR 2026) - "IDE-161, a first-in-class PARG inhibitor has entered clinical trials. QLS1403 demonstrates superior potency, sustained efficacy in PARPi-resistant and T-Dxd-resistant cancer cell lines, while displaying favorable safety. These compelling data support its clinical evaluation as a new therapeutics for patients with HRD-positive cancers with acquisition of resistance to PARPi or potentially other existing treatments, such as T-Dxd."

Clinical • Preclinical • Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • HRD